sanofi vigil neuroscience

News

Sanofi buys Vigil Neuroscience for $470m

Sanofi to buy Vigil Neuroscience in $470M deal (update)

Sanofi (NASDAQ:SNY) said Wednesday it agreed to acquire clinical-stage biotechnology company Vigil Neuroscience (NASDAQ:VIGL) for $470M in cash, potentially reaching $600M with milestone payments. Following a trading halt,

· 2d · on MSN

Vigil Neuroscience Stock Triples as Drugmaker Agrees to Acquisition by Sanofi

· 3d

Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi

Fierce Biotech2d

Sanofi inks $470M Vigil buyout, brushing off rivals' failures to join Novartis in Alzheimer's race

Sanofi’s 11 months watching over Vigil Neuroscience have led to a $470 million buyout. | Sanofi’s 11 months watching over ...

PharmTech1d

Sanofi to Acquire Vigil Neuroscience to Expand Neurodegenerative Disease Pipeline

Sanofi is acquiring Vigil Neuroscience, a biotech firm focused on novel neurodegenerative disease therapies, to boost its ...

Nasdaq3d

Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline

Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline Houman Ashrafian, MD, PhDHead of Research and Development ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

News

Sanofi buys Vigil Neuroscience for $470m

Trending now